What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His main research concerns Internal medicine, Breast cancer, Oncology, Surgery and Metastatic breast cancer.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology and Gynecology.
His Breast cancer research incorporates elements of Tumor progression, Clinical trial, Pathology and Metastasis.
His Oncology study incorporates themes from Antiestrogen, Exemestane, Tamoxifen and Trastuzumab.
His Surgery research integrates issues from Placebo and Family medicine.
In his research, Bevacizumab is intimately related to Docetaxel, which falls under the overarching field of Metastatic breast cancer.
His most cited work include:
- Landscape of somatic mutations in 560 breast cancer whole-genome sequences (1082 citations)
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma (874 citations)
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer (735 citations)
What are the main themes of his work throughout his whole career to date?
Luc Dirix mainly focuses on Internal medicine, Oncology, Breast cancer, Cancer and Cancer research.
The various areas that Luc Dirix examines in his Internal medicine study include Gastroenterology and Surgery.
His studies examine the connections between Oncology and genetics, as well as such issues in Circulating tumor cell, with regards to Prostate cancer.
Luc Dirix combines subjects such as Hazard ratio, Gene expression profiling and Pathology with his study of Breast cancer.
His Pathology research includes themes of Angiogenesis and Metastasis, Lymphangiogenesis.
His Cancer research research includes elements of Gene expression and Gene.
He most often published in these fields:
- Internal medicine (55.68%)
- Oncology (41.30%)
- Breast cancer (38.98%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (55.68%)
- Oncology (41.30%)
- Cancer research (20.42%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Oncology, Cancer research, Breast cancer and Cancer are his primary areas of study.
His work on Chemotherapy, Clinical trial, Metastatic breast cancer and Cohort as part of general Internal medicine study is frequently connected to In patient, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.
His work deals with themes such as Circulating tumor cell, Adverse effect, Proportional hazards model, Biomarker and Prostate cancer, which intersect with Oncology.
Luc Dirix has included themes like Cell culture, E2F1, Cistrome, Inflammatory breast cancer and Gene in his Cancer research study.
His Breast cancer research focuses on subjects like Hazard ratio, which are linked to Placebo.
His Cancer study integrates concerns from other disciplines, such as Cytotoxic T cell and PI3K/AKT/mTOR pathway.
Between 2016 and 2021, his most popular works were:
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial (554 citations)
- Pan-cancer analysis of whole genomes (538 citations)
- Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial (260 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
The scientist’s investigation covers issues in Internal medicine, Oncology, Clinical trial, Avelumab and Prostate cancer.
His research on Internal medicine frequently links to adjacent areas such as Surgery.
His Oncology study combines topics from a wide range of disciplines, such as Circulating tumor cell, Metastatic breast cancer, Sonidegib, Pathology and Triple-negative breast cancer.
His Clinical trial research is multidisciplinary, relying on both Survival analysis and Chemotherapy.
His work in Prostate cancer tackles topics such as Clinical significance which are related to areas like Mrna expression, Cabazitaxel, Taxane and Median time.
Inflammatory breast cancer is the focus of his Breast cancer research.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
